Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (12)	7/10/2001 9:31:02 PM
From: $Mogul	Read Replies (2) \| Respond to of 161

I don't see any weakness here..rather a very savy and potentially very profitable move.. Eos will pay an upfront technology access fee, milestone payments and royalties on net sales of any resulting products. Eos will be responsible for product development, manufacturing and marketing of any products generated through the collaboration. ``Seattle Genetics is committed to discovering and developing leading-edge antibody-drug conjugate technology for use with our internal programs as well as to partner with other companies,'' stated H. Perry Fell, Ph.D., Chief Executive Officer of Seattle Genetics. ``By working with Eos, we benefit by leveraging our internal work into a collaboration with a company committed to developing therapeutically useful products based on novel discoveries from analyzing the human genome. Eos benefits by gaining access to a sophisticated arsenal of next generation payloads to couple to their proprietary antibodies.''